Combining radiotherapy with immunotherapy

Biomarker driven clinical trials

Decoding breast cancer predisposition genes

Epirubicin and cyclophosphamide before docetaxel in early breast cancer

Matched mutations and long term letrozole for breast cancer

Matched mutations in the progression of metastatic breast cancer

PD-1 therapy with eribulin for triple negative MBC

Everolimus extends PFS for HR positive, HER2 negative breast cancer

Neoadjuvant abemaciclib for HR positive, HER negative breast cancer

TCHP with/out oestrogen for HR/HER positive breast cancer

Whole exome and transcriptome sequencing of resistant ER positive metastatic breast cancer

Pacritinib versus best available therapy for low platelet Myelofibrosis